For US Healthcare Providers Only

For US Healthcare Providers Only

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

TOP

IMPORTANT SAFETY INFORMATION

Indication

Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history

Important Safety Information for Makena
(hydroxyprogesterone caproate injection)

  • Do not use Makena in women with any of the following conditions:

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

FDA Approved Status

There may be some confusion about the current status of Makena. Makena remains available to patients and prescribers. If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

To learn more about current medical society guidelines, you can visit the American College of Obstetricians and Gynecologists and/or the Society for Maternal-Fetal Medicine website(s).

If you have any questions, we welcome you to contact AMAG Pharmaceuticals at 1-877-411-2510 or by emailing medinfoUS@covispharma.com.

AMAG Pharmaceuticals, Makena, Makena Care Connection, and the logo designs presented in this material are trademarks of Covis Pharma GmbH. All rights reserved. ©2022 Covis Pharma GmbH. PP-MKN-US-00692 07/22